

IMPORTANT FACTS ABOUT GENETIC AMYOTROPHIC LATERAL SCLEROSIS (ALS)

1. Genetics plays an important role in ALS.¹

The risk of developing ALS is different across continents and ethnicities, with some of these differences determined by underlying genetic variation.⁵ Different mutations in the same ALS-associated gene can result in different rates of disease progression.¹

2. Approximately 5–10% of all ALS cases are associated with a genetic mutation.²

Although most cases of ALS are not associated with known genetic mutations, 5-10% of patients with ALS have a family history of the disease.² Even patients without a family history of ALS can have a genetic mutation, and at least 25 genes are known to play a role in the development of ALS.⁵ The first ALS-linked gene identified was the *SOD1* gene in 1993.⁶ Mutations in another gene, the *C9orf72* gene are most common among European patients, accounting for approximately 34% of cases with a known family history of ALS and approximately 5% of cases without a family history of ALS.²

3. Patients with seemingly “sporadic” ALS (i.e., unknown cause(s) of ALS) may have a genetic form of ALS.³

Genetic forms of ALS have been identified in those with a family history of ALS as well as in those who do not have a known family history of ALS.³

4. There are many reasons to undergo genetic testing after an ALS diagnosis.⁴

People living with ALS often have a lot of questions, including: Why did I develop this disease? What is the likelihood I will pass it to my children? How quickly will my disease progress? Genetic testing may help an individual understand a diagnosis, discover if there are opportunities to participate in clinical research trials targeting genetic forms of ALS, and help inform long-term life choices.⁴

5. Ongoing clinical trials may be options for people with genetic forms of ALS.

Clinical trials focusing on genetic causes of ALS are ongoing (<https://www.clinicaltrials.gov>).

ALS, amyotrophic lateral sclerosis; SOD1, superoxide dismutase 1; C9orf72, chromosome 9 open reading frame 72.

References:

1. Kenna KP, McLaughlin RL, Byrne S, et al. Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. *J Med Genet.* 2013;50(11):776–783. 2. Zou ZY, Zhou ZR, Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry.* 2017;88(7):540–549. 3. Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. *Nat Rev Dis Primers.* 2017;3:17071. 4. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. *Genet Med.* 2017;19(3):267–274. 5. Pansarasa O, Bordini M, Diamanti L, et al. SOD1 in Amyotrophic lateral sclerosis: “Ambivalent” behavior connected to the disease. *Int J Mol Sci.* 2018;19(5):1345.